Table 3. Comparison of prognostic value of candidate markers in each AJCC stage of melanoma in discovery patient cohort#.
| Factor | AJCC I (N = 55) | AJCC II (N = 93) | AJCC III (N = 69) | AJCC IV (N = 37) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
| Age | 1.01 | 0.96–1.06 | 0.784 | 1.01 | 0.99–1.03 | 0.406 | 0.99 | 0.97–1.02 | 0.504 | 1.02 | 0.99–1.06 | 0.225 |
| Gender | 1.19 | 0.23–6.26 | 0.834 | 1.04 | 0.50–2.20 | 0.915 | 1.81 | 0.93–3.53 | 0.080 | 3.05 | 1.11–8.39 | 0.031 |
| Thickness | 1.79 | 0.36–8.94 | 0.479 | 1.07 | 1.01–1.13 | 0.018 | - | - | - | - | - | - |
| Ulceration | - | - | - | 3.05 | 1.45–6.44 | 0.003 | - | - | - | - | - | - |
| BRAF | 3.86 | 0.81–18.30 | 0.089* | 0.81 | 0.38–1.70 | 0.575 | 0.87 | 0.46–1.65 | 0.673 | 0.91 | 0.38–2.17 | 0.824 |
| Dicer | 0.43 | 0.08–2.24 | 0.312 | 1.85 | 0.82–4.18 | 0.139 | 0.93 | 0.48–1.82 | 0.833 | 1.59 | 0.52–4.89 | 0.421 |
| Fbw7 | 3.03 | 0.50–18.25 | 0.227 | 1.81 | 0.89–3.71 | 0.103 | 0.68 | 0.35–1.33 | 0.263 | 0.91 | 0.37–2.23 | 0.828 |
| MMP2 | 1.55 | 0.14–17.75 | 0.726 | 3.85 | 1.69–8.77 | 0.001* | 0.94 | 0.42–2.08 | 0.874 | 0.95 | 0.36–2.53 | 0.923 |
| P27 | 0.41 | 0.08–2.02 | 0.274 | 2.83 | 1.39–5.78 | 0.004 | 2.12 | 1.11–4.08 | 0.024* | 2.27 | 0.94–5.47 | 0.068* |
| Tip60 | 0.55 | 0.06–4.79 | 0.588 | 0.41 | 0.18–0.93 | 0.033 | 0.91 | 0.44–1.90 | 0.799 | 0.36 | 0.11–1.16 | 0.085 |
#
this cohort of patients has survival data for each of the six biomarkers
*
selected marker for confirmaton analysis in expanded patient cohort